[Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
Ten patients with surgically and pathologically confirmed ovarian cancer were treated by intraperitoneal (IP) chemotherapy of 20-25 mg/m2 of cisplatin. Total platinum concentrations in plasma, ascitic fluid and urine were determined by flameless atomic absorption spectrophotometry. The peak of total platinum concentration in ascitic fluid was 18.75 times greater than that in plasma. The half-life of the elimination for total ascites platinum and total plasma platinum were 39.9 hours and 70.6 hours respectively. Peritoneal clearance of cisplatin was 6.1 ml/min whereas body clearance of cisplatin was 15.3 ml/min. 24 hours following administration, 13.53% of cisplatinum had been excreted through the urine. The results indicate that there is pharmacokinetic advantage to be gained by using IP chemotherapy of cisplatin. Because the half-life of cisplatin in plasma is longer, therefore, the interval of chemotherapy should be three weeks or more.
Han
G R
GR
Dalian Rail-Way Hospital.
Cai
G F
GF
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D006801:Humans; D007274:Injections, Intraperitoneal; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010537:Peritoneum / Q000378:metabolism
D002945:Cisplatin